REG-Arix Bioscience PLC Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

Arix BioscienceAnnouncement

13/11/2023 16:00

============

   Arix Bioscience PLC (ARIX)
   Correction: Portfolio Company Aura Biosciences Announces Closing of $99
   million Public Offering of Common Stock

   13-Nov-2023 / 16:00 GMT/BST

   ══════════════════════════════════════════════════════════════════════════

                                        

   The following  amendment has  been  made to  the “Portfolio  Company  Aura
   Biosciences Announces Closing  of $99  million Public  Offering of  Common
   Stock” announcement released on 10/11/2023 at 08:00 GMT under EQS News  ID
   1770215.

    

   Some definitions of the “Company” have been amended to reflect the defined
   name of the portfolio company, “Aura”, throughout the release.

    

   All other information remains unchanged.  The fully amended text is  shown
   below:

    

                              Arix Bioscience plc

                                        

   Portfolio Company Aura Biosciences Announces Closing of $99 million Public
                            Offering of Common Stock

                                        

   LONDON, 13 November 2023:  Arix Bioscience plc  (“Arix” or the  “Company”)
   (LSE: ARIX), a transatlantic venture capital company focused on  investing
   in breakthrough  biotechnology companies,  notes that  its Core  Portfolio
   company, Aura  Biosciences  (NASDAQ:  AURA) (“Aura”),  has  announced  the
   closing of its underwritten  public offering of  11,000,000 shares of  its
   common stock at a price to the public of $9.00 per share.

    

   Aura  received  net  proceeds  from  the  Offering,  after  deducting  the
   underwriting discounts and commissions and estimated offering expenses, of
   approximately $92.6 million. Aura intends to use the net proceeds from the
   Offering, together with its existing cash, cash equivalents and marketable
   securities to advance the  clinical development of belzupacap  sarotalocan
   for the  treatment  of choroidal  melanoma  and choroidal  metastasis,  to
   develop the platform  and for  general corporate  purposes. Aura  believes
   that the net proceeds from this offering, together with its existing cash,
   cash equivalents and  marketable securities,  will enable it  to fund  its
   operating expenses and  capital expenditure requirements  into the  second
   half of 2026.

    

   Arix holds 1,508,483  shares in Aura.  The holding value  of these  shares
   will continue to be determined by the market price of Aura’s shares.

    

   The full  text  from Aura’s  announcement  can  be accessed  on  the  Aura
   Biosciences website here:  1 https://ir.aurabiosciences.com/press-releases

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 2 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    3 arix@powerscourt-group.com

    

    

    

   About Arix Bioscience plc

   Arix Bioscience plc is a transatlantic venture capital company focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  4 www.arixbioscience.com

    

   ══════════════════════════════════════════════════════════════════════════

   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCM
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   284573
   EQS News ID:    1772109


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    5 fncls.ssp?fn=show_t_gif&application_id=1772109&application_name=news&site_id=refinitiv

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5c002e93d4b214c9735c1f5700b257e2&application_id=1772109&site_id=refinitiv&application_name=news
   2. mailto:charlotte@arixbioscience.com
   3. mailto:arix@powerscourt-group.com
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1772109&site_id=refinitiv&application_name=news


============